Recent MYNZ News
- Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial • GlobeNewswire Inc. • 05/20/2024 12:01:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 05/10/2024 09:20:09 PM
- Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. • GlobeNewswire Inc. • 05/07/2024 12:01:00 PM
- Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic • GlobeNewswire Inc. • 04/25/2024 01:29:00 PM
- Mainz Biomed Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/09/2024 12:01:00 PM
- Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment • GlobeNewswire Inc. • 03/19/2024 12:01:00 PM
- Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options • GlobeNewswire Inc. • 03/18/2024 12:01:00 PM
- Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations • GlobeNewswire Inc. • 03/12/2024 12:01:00 PM
- Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic • GlobeNewswire Inc. • 03/05/2024 01:01:00 PM
- Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community • GlobeNewswire Inc. • 02/27/2024 01:01:00 PM
- Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® • GlobeNewswire Inc. • 02/22/2024 01:01:00 PM
- Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy • GlobeNewswire Inc. • 02/21/2024 01:01:00 PM
- Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany • GlobeNewswire Inc. • 02/06/2024 01:01:00 PM
- Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium • GlobeNewswire Inc. • 01/11/2024 01:01:00 PM
- Mainz Biomed Provides Year-End Corporate Review 2023 • GlobeNewswire Inc. • 01/09/2024 01:01:00 PM
- Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees • GlobeNewswire Inc. • 12/19/2023 01:01:00 PM
- Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland • GlobeNewswire Inc. • 12/12/2023 01:01:00 PM
- Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers • GlobeNewswire Inc. • 12/05/2023 02:01:55 PM
- Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast • GlobeNewswire Inc. • 11/29/2023 01:01:00 PM
- Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 01:01:00 PM
- Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/16/2023 01:01:04 PM
- Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering • GlobeNewswire Inc. • 11/15/2023 02:01:48 PM
- Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering • GlobeNewswire Inc. • 11/13/2023 02:00:24 PM
- Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test • GlobeNewswire Inc. • 11/09/2023 01:01:00 PM
- Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA • GlobeNewswire Inc. • 11/07/2023 01:01:00 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM